Literature DB >> 34282295

Clinical impact of PET/MRI in oligometastatic colorectal cancer.

Felipe S Furtado1,2, Krista E Suarez-Weiss3, Mark Vangel1,2,4, Jeffrey W Clark1, James C Cusack1, Theodore Hong1, Lawrence Blaszkowsky1,5, Jennifer Wo1, Robin Striar2, Lale Umutlu6, Heike E Daldrup-Link7, David Groshar8, Ricciardi Rocco1, Liliana Bordeianou1, Mark A Anderson1, Amirkasra Mojtahed1, Motaz Qadan1, Cristina Ferrone1, Onofrio A Catalano9,10.   

Abstract

BACKGROUND: Oligometastatic colorectal cancer (CRC) is potentially curable and demands individualised strategies.
METHODS: This single-centre retrospective study investigated if positron emission tomography (PET)/magnetic resonance imaging (MR) had a clinical impact on oligometastatic CRC relative to the standard of care imaging (SCI). Adult patients with oligometastatic CRC on SCI who also underwent PET/MR between 3/2016 and 3/2019 were included. The exclusion criterion was lack of confirmatory standard of reference, either surgical pathology, intraoperative gross confirmation or imaging follow-up. SCI consisted of contrast-enhanced (CE) computed tomography (CT) of the chest/abdomen/pelvis, abdominal/pelvic CE-MR, and/or CE whole-body PET/CT with diagnostic quality (i.e. standard radiation dose) CT. Follow-up was evaluated until 3/2020.
RESULTS: Thirty-one patients constituted the cohort, 16 (52%) male, median patient age was 53 years (interquartile range: 49-65 years). PET/MR and SCI results were divergent in 19% (95% CI 9-37%) of the cases, with PET/MR leading to management changes in all of them. The diagnostic accuracy of PET/MR was 90 ± 5%, versus 71 ± 8% for SCI. In a pairwise analysis, PET/MR outperformed SCI when compared to the reference standard (p = 0.0412).
CONCLUSIONS: These findings suggest the potential usefulness of PET/MR in the management of oligometastatic CRC.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34282295      PMCID: PMC8476553          DOI: 10.1038/s41416-021-01494-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  37 in total

Review 1.  The oligometastatic state - separating truth from wishful thinking.

Authors:  David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

2.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

3.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

4.  Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series.

Authors:  A E M van der Pool; R A Damhuis; J N M Ijzermans; J H W de Wilt; A M M Eggermont; R Kranse; C Verhoef
Journal:  Colorectal Dis       Date:  2012-01       Impact factor: 3.788

Review 5.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

6.  Epidemiology and management of liver metastases from colorectal cancer.

Authors:  Sylvain Manfredi; Côme Lepage; Cyril Hatem; Olivier Coatmeur; Jean Faivre; Anne-Marie Bouvier
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

7.  Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

Authors:  René Adam; Dennis A Wicherts; Robbert J de Haas; Oriana Ciacio; Francis Lévi; Bernard Paule; Michel Ducreux; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  Hematogenous metastatic patterns of curatively resected colon cancer were different from those of stage IV and autopsy cases.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Hiroko Kamata
Journal:  Jpn J Clin Oncol       Date:  2013-01-30       Impact factor: 3.019

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  3 in total

1.  Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.

Authors:  Marcelo A Queiroz; Cinthia D Ortega; Felipe R Ferreira; Fernanda C Capareli; Sergio C Nahas; Giovanni G Cerri; Carlos A Buchpiguel
Journal:  Mol Imaging Biol       Date:  2021-11-09       Impact factor: 3.488

Review 2.  Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis.

Authors:  Seyed Ali Mirshahvalad; Ricarda Hinzpeter; Andres Kohan; Reut Anconina; Roshini Kulanthaivelu; Claudia Ortega; Ur Metser; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-16       Impact factor: 10.057

Review 3.  Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection.

Authors:  Francesco Crafa; Serafino Vanella; Onofrio A Catalano; Kelsey L Pomykala; Mario Baiamonte
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.